Answers are grounded in this paper and cite their sources.
Experimental study reveals suppression of macrophage inflammation by periodontal stem cells in oral ulcer models, highlighting pyrimidine metabolism as a therapeutic target.
Periodontal ligament stem cells (PDLSCs) possess potent immunomodulatory and regenerative properties, positioning them as a promising therapeutic strategy for oral inflammatory diseases. However, the metabolic mechanisms governing PDLSC–immune cell crosstalk, particularly in the context of macrophage-driven inflammation, remain incompletely understood. A Transwell coculture model of PDLSCs and THP-1–derived macrophages was established to investigate PDLSC-mediated regulation of macrophage inflammasome activation and inflammation. Transcriptomic, proteomic, and metabolomic profiling with integrated pathway analysis identified metabolic pathways associated with PDLSC-mediated immunomodulation. Triacetyluridine (TAU) was subsequently investigated as a pyrimidine metabolism-related modulator using network pharmacology, functional enrichment, and molecular docking analyses. Its anti-inflammatory effects were evaluated in macrophages, and tissue-reparative effects were assessed in a murine oral ulcer model. PDLSC coculture markedly suppressed activation of the NLRP3 inflammasome and its downstream mediators, including caspase-1, IL-1β, and IL-18, at both transcriptional and protein levels. In the murine oral ulcer model, PDLSC treatment preserved epithelial architecture, reduced immune cell infiltration, and enhanced expression of regenerative markers. Integrated multiomics analyses identified pyrimidine metabolism as a prominent metabolic pathway altered in macrophages cocultured with PDLSCs, characterized by coordinated changes in pyrimidine metabolites and metabolism-associated proteins. TAU-associated analyses identified pyrimidine metabolism as a principal pathway, with UPP1, TYMP, and DPYD as representative targets, and docking predicted potential interactions of TAU with these enzymes. TAU treatment reproduced several anti-inflammatory and tissue-reparative features associated with PDLSC treatment, suppressing inflammasome-related gene expression in vitro and promoting mucosal healing in vivo. PDLSCs modulate macrophage inflammation in association with coordinated remodeling of Pyrimidine metabolism. Functional studies with TAU further support a role for pyrimidine metabolic regulation in controlling inflammatory responses and tissue repair, highlighting this metabolic pathway as a potential therapeutic target for oral inflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: